Actively Recruiting
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
Led by Fujian Medical University Union Hospital · Updated on 2024-03-15
40
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.
CONDITIONS
Official Title
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Diagnosed with resectable or borderline resectable pancreatic cancer based on pathology and imaging
- No prior anti-tumor treatment
- At least one measurable tumor lesion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- No participation in other clinical studies before or during treatment
- Willing to participate voluntarily and sign informed consent
You will not qualify if you...
- History of any other malignant tumor within the past 5 years except fully removed basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- Vaccination with live vaccines within 4 weeks before enrollment or during the study
- Active autoimmune diseases or history of autoimmune diseases within 4 weeks before enrollment
- Previous allogeneic bone marrow or organ transplantation
- Active gastric or duodenal ulcers, ulcerative colitis, active gastrointestinal bleeding, or conditions risking gastrointestinal bleeding or perforation
- Significant bleeding events within 3 months before enrollment or hemoptysis within 4 weeks
- Thromboembolic events including stroke or transient ischemic attacks within 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
Research Team
Y
Yu Pan, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here